Aurobindo Pharma Limited has informed the Exchange about completion of US FDA Inspection at Unit II of Eugia Pharma Specialities Ltd.
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aurobindo Pharma has informed the stock exchange that the US FDA has completed its inspection at Unit II of Eugia Pharma Specialities Ltd., its subsidiary that focuses on injectable and oncology formulations. The filing only states the inspection was completed; it does not specify whether the outcome included any adverse observations (Form 483) or a clean closure (EIR). Eugia is a key manufacturing arm for Aurobindo's injectables and oncology business, which supplies the US market — one of its largest revenue contributors. Investors typically track such updates closely because any negative FDA findings could disrupt US product supplies and earnings.
Short-term impact depends on inspection outcome — if clean, it reinforces compliance credibility and supports steady US supplies; if observations were issued, expect short-term pressure on the stock. Shareholders should watch for a follow-up update specifying EIR or Form 483 status.